Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adamantane SCHEMBL870112 | 1.00 | CYP2C9 (0.43) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL28551331 | 0.94 | CYP2C9 (0.40) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL317246 | 0.94 | CYP2C9 (0.40) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL21433651 | 0.94 | CYP2C9 (0.40) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL18065809 | 0.94 | CYP2C9 (0.40) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL12761 | 0.93 | CYP2C9 (0.46) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL1527414 | 0.93 | CYP2C9 (0.46) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL29707714 | 0.93 | CYP2C9 (0.46) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL9016497 | 0.93 | CYP2C9 (0.46) | CYP2C9LMNASLC22A2SLC22A1GRIN2D | |
| Adamantane SCHEMBL7154373 | 0.88 | CYP2C9 (0.38) | CYP2C9LMNAPOLBTHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121591614-B | Adamantane derivative and synthesis method and application thereof | Shandong Xinhua Pharmaceutical Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20250257111-A1 | Supramolecular Complex of a Biomolecule | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-08-14 | — | — | US | claimed |
| EP-4511382-A1 | SUPRAMOLECULAR COMPLEX OF A BIOMOLECULE | Cambridge Enterprise Limited (GB) | 2025-02-26 | — | — | EP | claimed |
| EP-3702393-B1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM INC (JP) | 2025-01-15 | — | — | EP | claimed |
| WO-2023203201-A1 | SUPRAMOLECULAR COMPLEX OF A BIOMOLECULE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-10-26 | — | — | WO | claimed |
| CN-116034090-A | CHA type zeolite and preparation method thereof | 东曹株式会社 | 2023-04-28 | — | — | CN | claimed |
| EP-3322291-B1 | ANTIMICROBIAL COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2023-04-12 | — | — | EP | claimed |
| US-11084888-B2 | Production method for low inclusion rate polyrotaxane | ASM, Inc. (JP) | 2021-08-10 | — | — | US | claimed |
| US-20200339709-A1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM, Inc. (JP) | 2020-10-29 | — | — | US | claimed |
| EP-3702393-A1 | PRODUCTION METHOD FOR LOW INCLUSION RATE POLYROTAXANE | ASM Inc. (JP) | 2020-09-02 | — | — | EP | claimed |
| US-20140154562-A1 | NEGATIVE ELECTRODE FOR RECHARGEABLE LITHIUM BATTERY, METHOD OF PREPARING THE SAME AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2014-06-05 | — | — | US | claimed |
| CN-103539690-A | Intermediate for synthesis of amantadine drugs and its preparation method and use | HEFEI JIUNUO MEDICAL TECHNOLOGY CO LTD | 2014-01-29 | — | — | CN | claimed |
| CN-103274968-A | Method for producing amantadine compound | SHANGHAI TWISUN BIO PHARM CO LTD | 2013-09-04 | — | — | CN | claimed |
| WO-2013034707-A1 | USE OF ADAMANTANE DERIVATIVES FOR THE TREATMENT OF ACTINIC KERATOSIS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-03-14 | — | — | WO | claimed |
| CN-102046008-A | Antimicrobial polymers and uses thereof | DSM IP ASSETS BV | 2011-05-04 | — | — | CN | claimed |
| US-20090072191-A1 | Nor-Seco-Bis-Nor-Seco, Tris-Nor-Seco, and Higher Nor-Seco-Cucurbit[n]Uril Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-03-19 | — | — | US | claimed |
| WO-2007106144-A1 | NOR-SECO-, BIS-NOR-SECO, TRIS-NOR-SECO- AND HIGHER NOR-SECO- CUCURBIT[n]URIL COMPOUNDS | UNIVERSITY OF MARYLAND (US) | 2007-09-20 | — | — | WO | claimed |
| CN-1869061-A | Peptidomimetic protease inhibitors | LILLY CO ELI (US) | 2006-11-29 | — | — | CN | claimed |
| US-6384083-B1 | CONTROLLING VIRUSES OF BORNAVIRIDAE FAMILY BY ADMINISTERING ADAMANTANE AMINES TO HUMAN AND ANIMALS AT THERAPEUTICALLY EFFECTIVE DOSAGE BY MEANS SELECTED FROM ORAL, PARENTERAL, INTRAMUSCULAR, SUBCUTANEOUS, INTRADERMAL AND TOPICAL | Ludwig, Hanns (DE) | 2002-05-07 | — | — | US | claimed |
| EP-0566680-B1 | LAYERED OXIDE MATERIALS AND SWOLLEN AND PILLARED FORMS THEREOF | MOBIL OIL CORP (US) | 1998-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257111-A1 | Supramolecular Complex of a Biomolecule | CCR8, IGFBP1, IGFBP2 | CYP2C9 1144/4885LMNA 3929/4885SLC22A2 4348/4885 |
| US-20090072191-A1 | Nor-Seco-Bis-Nor-Seco, Tris-Nor-Seco, and Higher Nor-Seco-Cucurbit[n]Uril Compounds | BYSL, URB2, NONO | CYP2C9 1438/4885LMNA 2463/4885SLC22A2 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.